Gene Editing Pioneering Mammoth Biosciences Startup Continues to Raise Money—Now $195m

A San Francisco Bay Area biotech firm just raised $195 million to develop next-generation CRISPR products, pursuing their mission to cure and detect diseases. With a valuation of over $1 billion, this startup joins the ranks of “unicorn” for a good reason. The core founding team centers around a Nobel Prize winning CRISPR guru. That is UC Berkeley’s Jennifer Doudna, a pioneer in the field of gene editing. Mammoth Biosciences’ most recent financing is composed of $150 million Series D led by Redmile Group following a $45 million Series C in late 2020 also led by private equity and lender Redmile Group and Foresite Capital, but also participation from Amazon and other existing investors.  Why is so much money going into this startup just founded in 2017. Investors are betting on the talent and leadership backing this CRISP startup, one that proclaims to lead the revolution in precision medicine, one at the forefront of developing differentiated next-generation CRISPR systems leading to the advancement of novel treatment and diagnosis options. Can this startup ultimately be successful targeting a pipeline of new one-time cures and molecular diagnostics at the same time, or will they ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee